Eledon Pharmaceuticals is a clinical-stage biopharmaceutical enterprise dedicated to discovering and developing innovative immune-modulating therapies designed to treat life-threatening conditions, organ transplant rejections, xenotransplantation challenges, and autoimmune disorders. Its primary investigational candidate, tegoprubart, targets the CD40 ligand pathway to modulate immune responses effectively without causing widespread lymphocyte depletion.